Archive | Health Professionals

BMS’ Opdivo/Yervoy improves long-term survival for melanoma patients

Bristol Myers Squibb’s Opdivo (nivolumab) plus Yervoy (ipilimumab) combination has demonstrated ‘durable improvement in survival’, according to new long-term data from a Phase III trial.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Screening and Identification of Key Biomarkers in Melanoma

Malignant melanoma is uncommon worldwide, accounting for only ?1% of all malignant tumors.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Vidutolimod/Nivolumab Under Evaluation in PD-1-Refractory Advanced Melanoma

The safety and efficacy of the combination of vidutolimod (CMP-001) and nivolumab (Opdivo) is currently under investigation in patients with PD-1–refractory advanced melanoma, as part of the ongoing phase 2 CMP-001-010 trial (NCT04698187).1

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Australian researchers lead world in successful trial of new cancer treatment

In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest